Lexicon Pharmaceuticals Stock Price To Earnings To Growth

LXRX Stock

USD 0.81 0.05 5.81%

Lexicon Pharmaceuticals fundamentals help investors to digest information that contributes to Lexicon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lexicon Stock. The fundamental analysis module provides a way to measure Lexicon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexicon Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lexicon Pharmaceuticals Company Price To Earnings To Growth Analysis

Lexicon Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current Lexicon Pharmaceuticals Price To Earnings To Growth

(0.14) X

Most of Lexicon Pharmaceuticals' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexicon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lexicon Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Lexicon Pharmaceuticals is extremely important. It helps to project a fair market value of Lexicon Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Lexicon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexicon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexicon Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.39	0.51	-0.57	-0.11	0.47	0.18	0.88	0.78	0.98	0.33	0.53	0.35	0.32	0.43	0.75	0.1	0.1	-0.19	-0.16	0.62	-0.16	0.55	0.53	-0.4
Total Stockholder Equity	0.39		0.12	-0.55	0.31	0.18	-0.35	0.35	0.1	0.4	0.45	-0.12	-0.29	0.18	-0.09	0.34	0.43	0.54	-0.38	-0.25	0.34	0.31	0.3	0.25	-0.1
Current Deferred Revenue	0.51	0.12		-0.29	-0.43	0.59	0.09	0.64	0.57	0.61	-0.08	0.35	0.28	-0.25	0.37	0.09	-0.41	-0.13	0.31	0.45	0.72	-0.51	-0.05	-0.02	0.14
Net Debt	-0.57	-0.55	-0.29		-0.33	-0.17	0.48	-0.37	-0.15	-0.53	-0.34	-0.16	0.4	-0.42	-0.1	-0.58	-0.09	-0.55	0.63	0.41	-0.58	-0.22	-0.26	-0.14	0.42
Retained Earnings	-0.11	0.31	-0.43	-0.33		-0.26	-0.06	-0.16	-0.23	-0.13	0.34	-0.75	-0.43	0.52	-0.76	-0.02	0.51	0.6	-0.84	-0.85	0.03	0.58	0.56	0.48	-0.61
Accounts Payable	0.47	0.18	0.59	-0.17	-0.26		0.04	0.65	0.73	0.47	0.24	0.25	0.51	0.0	0.24	0.44	-0.07	-0.48	0.14	0.12	0.23	-0.1	0.24	0.21	-0.19
Net Receivables	0.18	-0.35	0.09	0.48	-0.06	0.04		0.3	0.36	0.23	0.13	0.04	0.56	-0.02	0.03	-0.24	-0.17	-0.2	0.2	0.01	-0.11	-0.11	0.47	0.58	-0.22
Short Term Investments	0.88	0.35	0.64	-0.37	-0.16	0.65	0.3		0.82	0.9	0.18	0.38	0.42	0.17	0.36	0.56	0.1	0.0	-0.09	0.02	0.6	-0.14	0.57	0.59	-0.25
Total Liab	0.78	0.1	0.57	-0.15	-0.23	0.73	0.36	0.82		0.79	0.17	0.35	0.79	0.11	0.31	0.55	0.01	-0.42	0.14	0.02	0.47	-0.44	0.5	0.49	-0.37
Total Current Assets	0.98	0.4	0.61	-0.53	-0.13	0.47	0.23	0.9	0.79		0.34	0.47	0.38	0.16	0.39	0.61	0.02	0.13	-0.1	-0.05	0.67	-0.23	0.52	0.51	-0.34
Short Term Debt	0.33	0.45	-0.08	-0.34	0.34	0.24	0.13	0.18	0.17	0.34		-0.04	0.01	0.18	-0.08	0.22	0.15	0.3	-0.35	-0.38	-0.14	0.5	0.47	0.44	-0.44
Common Stock	0.53	-0.12	0.35	-0.16	-0.75	0.25	0.04	0.38	0.35	0.47	-0.04		0.3	0.04	0.92	0.52	-0.35	-0.32	0.34	0.39	0.08	-0.28	-0.17	-0.14	0.16
Long Term Debt	0.35	-0.29	0.28	0.4	-0.43	0.51	0.56	0.42	0.79	0.38	0.01	0.3		-0.2	0.3	0.15	-0.2	-0.73	0.55	0.28	-0.02	-0.56	0.21	0.25	-0.14
Property Plant Equipment	0.32	0.18	-0.25	-0.42	0.52	0.0	-0.02	0.17	0.11	0.16	0.18	0.04	-0.2		-0.01	0.57	0.53	0.22	-0.74	-0.76	0.08	0.41	0.6	0.53	-0.56
Good Will	0.43	-0.09	0.37	-0.1	-0.76	0.24	0.03	0.36	0.31	0.39	-0.08	0.92	0.3	-0.01		0.38	-0.31	-0.32	0.36	0.54	0.04	-0.28	-0.18	-0.13	0.34
Intangible Assets	0.75	0.34	0.09	-0.58	-0.02	0.44	-0.24	0.56	0.55	0.61	0.22	0.52	0.15	0.57	0.38		0.28	-0.07	-0.38	-0.38	0.33	0.06	0.4	0.3	-0.47
Treasury Stock	0.1	0.43	-0.41	-0.09	0.51	-0.07	-0.17	0.1	0.01	0.02	0.15	-0.35	-0.2	0.53	-0.31	0.28		0.29	-0.52	-0.48	-0.02	0.4	0.5	0.48	-0.12
Net Tangible Assets	0.1	0.54	-0.13	-0.55	0.6	-0.48	-0.2	0.0	-0.42	0.13	0.3	-0.32	-0.73	0.22	-0.32	-0.07	0.29		-0.64	-0.41	0.27	0.51	0.25	0.23	-0.12
Long Term Debt Total	-0.19	-0.38	0.31	0.63	-0.84	0.14	0.2	-0.09	0.14	-0.1	-0.35	0.34	0.55	-0.74	0.36	-0.38	-0.52	-0.64		0.84	-0.16	-0.68	-0.62	-0.52	0.61
Capital Surpluse	-0.16	-0.25	0.45	0.41	-0.85	0.12	0.01	0.02	0.02	-0.05	-0.38	0.39	0.28	-0.76	0.54	-0.38	-0.48	-0.41	0.84		-0.03	-0.54	-0.65	-0.54	0.84
Deferred Long Term Liab	0.62	0.34	0.72	-0.58	0.03	0.23	-0.11	0.6	0.47	0.67	-0.14	0.08	-0.02	0.08	0.04	0.33	-0.02	0.27	-0.16	-0.03		-0.44	0.18	0.15	-0.14
Short Long Term Debt	-0.16	0.31	-0.51	-0.22	0.58	-0.1	-0.11	-0.14	-0.44	-0.23	0.5	-0.28	-0.56	0.41	-0.28	0.06	0.4	0.51	-0.68	-0.54	-0.44		0.38	0.34	-0.26
Net Invested Capital	0.55	0.3	-0.05	-0.26	0.56	0.24	0.47	0.57	0.5	0.52	0.47	-0.17	0.21	0.6	-0.18	0.4	0.5	0.25	-0.62	-0.65	0.18	0.38		0.98	-0.69
Net Working Capital	0.53	0.25	-0.02	-0.14	0.48	0.21	0.58	0.59	0.49	0.51	0.44	-0.14	0.25	0.53	-0.13	0.3	0.48	0.23	-0.52	-0.54	0.15	0.34	0.98		-0.58
Capital Stock	-0.4	-0.1	0.14	0.42	-0.61	-0.19	-0.22	-0.25	-0.37	-0.34	-0.44	0.16	-0.14	-0.56	0.34	-0.47	-0.12	-0.12	0.61	0.84	-0.14	-0.26	-0.69	-0.58

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Lexicon Pharmaceuticals

Lexicon Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.0625)

At this time, Lexicon Pharmaceuticals' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Lexicon Pharmaceuticals has a Price To Earnings To Growth of -0.14 times. This is 119.72% lower than that of the Biotechnology sector and 104.46% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 102.86% higher than that of the company.

Lexicon Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexicon Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics of similar companies.

Lexicon Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.

Lexicon Fundamentals

	Return On Equity	-1.36
	Return On Asset	-0.44
	Operating Margin	(36.40) %
	Current Valuation	154.94 M
	Shares Outstanding	361.49 M
	Shares Owned By Insiders	1.15 %
	Shares Owned By Institutions	82.02 %
	Number Of Shares Shorted	28.65 M
	Price To Earning	21.02 X
	Price To Book	1.75 X
	Price To Sales	59.69 X
	Revenue	1.2 M
	Gross Profit	(52.68 M)
	EBITDA	(163.46 M)
	Net Income	(177.12 M)
	Cash And Equivalents	61.97 M
	Cash Per Share	0.34 X
	Total Debt	106.06 M
	Debt To Equity	0.36 %
	Current Ratio	3.85 X
	Book Value Per Share	0.49 X
	Cash Flow From Operations	(161.9 M)
	Short Ratio	10.26 X
	Earnings Per Share	(0.74) X
	Price To Earnings To Growth	(0.14) X
	Target Price	4.16
	Number Of Employees	285
	Beta	1.24
	Market Capitalization	312.11 M
	Total Asset	229.43 M
	Retained Earnings	(1.77 B)
	Working Capital	145 M
	Current Asset	171.5 M
	Current Liabilities	31.77 M
	Net Asset	229.43 M

About Lexicon Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC